| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hydatidiform Mole | 138 | 2023 | 279 | 21.050 |
Why?
|
| Uterine Neoplasms | 192 | 2023 | 1513 | 16.190 |
Why?
|
| Chorionic Gonadotropin | 73 | 2023 | 474 | 5.680 |
Why?
|
| Choriocarcinoma | 42 | 2022 | 123 | 4.900 |
Why?
|
| Trophoblastic Neoplasms | 68 | 2000 | 87 | 4.690 |
Why?
|
| Methotrexate | 38 | 2023 | 1720 | 4.050 |
Why?
|
| Ovarian Neoplasms | 143 | 2021 | 4823 | 3.920 |
Why?
|
| Pregnancy | 269 | 2023 | 29087 | 3.600 |
Why?
|
| Vacuum Curettage | 7 | 2021 | 48 | 2.760 |
Why?
|
| Dactinomycin | 27 | 2023 | 317 | 2.430 |
Why?
|
| Brazil | 18 | 2023 | 1263 | 2.200 |
Why?
|
| Placenta | 26 | 2022 | 1694 | 2.010 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 46 | 2023 | 11472 | 1.940 |
Why?
|
| Trophoblastic Tumor, Placental Site | 6 | 2016 | 14 | 1.810 |
Why?
|
| Hysterectomy | 26 | 2016 | 927 | 1.640 |
Why?
|
| Antimetabolites, Antineoplastic | 10 | 2020 | 640 | 1.610 |
Why?
|
| Pregnancy Outcome | 17 | 2021 | 2795 | 1.580 |
Why?
|
| Pregnancy Complications, Neoplastic | 11 | 2017 | 253 | 1.460 |
Why?
|
| Neoplasm Staging | 73 | 2021 | 11001 | 1.440 |
Why?
|
| Female | 470 | 2023 | 379592 | 1.410 |
Why?
|
| Neoplasms, Glandular and Epithelial | 14 | 2018 | 484 | 1.310 |
Why?
|
| Uterine Hemorrhage | 11 | 2017 | 255 | 1.300 |
Why?
|
| Leucovorin | 18 | 2021 | 624 | 1.290 |
Why?
|
| Chorionic Gonadotropin, beta Subunit, Human | 14 | 2015 | 73 | 1.180 |
Why?
|
| Cystadenocarcinoma, Serous | 19 | 2020 | 450 | 1.150 |
Why?
|
| Trophoblasts | 11 | 2017 | 215 | 1.110 |
Why?
|
| Drug Resistance, Neoplasm | 17 | 2023 | 5163 | 1.080 |
Why?
|
| Gynecologic Surgical Procedures | 4 | 2018 | 336 | 1.040 |
Why?
|
| Fallopian Tube Neoplasms | 14 | 2020 | 324 | 0.990 |
Why?
|
| Neoplasm Recurrence, Local | 38 | 2023 | 9185 | 0.970 |
Why?
|
| Etoposide | 14 | 2023 | 637 | 0.960 |
Why?
|
| Humans | 474 | 2023 | 742088 | 0.950 |
Why?
|
| Maternal Age | 6 | 2016 | 802 | 0.930 |
Why?
|
| Retrospective Studies | 89 | 2023 | 77098 | 0.910 |
Why?
|
| New England | 16 | 2017 | 1021 | 0.890 |
Why?
|
| Watchful Waiting | 2 | 2017 | 491 | 0.880 |
Why?
|
| Adult | 191 | 2023 | 213712 | 0.860 |
Why?
|
| Hyperthyroidism | 3 | 2022 | 293 | 0.850 |
Why?
|
| Dilatation and Curettage | 9 | 2012 | 56 | 0.800 |
Why?
|
| Adenocarcinoma, Clear Cell | 11 | 2020 | 221 | 0.800 |
Why?
|
| Peritoneal Neoplasms | 19 | 2020 | 663 | 0.770 |
Why?
|
| Endometrial Neoplasms | 14 | 2020 | 1351 | 0.730 |
Why?
|
| Cohort Studies | 30 | 2023 | 40450 | 0.700 |
Why?
|
| Remission Induction | 16 | 2020 | 2384 | 0.690 |
Why?
|
| Fallopian Tube Diseases | 2 | 2016 | 62 | 0.660 |
Why?
|
| Young Adult | 33 | 2021 | 56350 | 0.660 |
Why?
|
| Ovary | 16 | 2018 | 981 | 0.650 |
Why?
|
| Uterine Cervical Neoplasms | 15 | 2021 | 2011 | 0.650 |
Why?
|
| Antineoplastic Agents | 30 | 2021 | 13655 | 0.640 |
Why?
|
| Curettage | 3 | 2016 | 73 | 0.640 |
Why?
|
| Fallopian Tubes | 5 | 2018 | 182 | 0.630 |
Why?
|
| Cyclophosphamide | 15 | 2023 | 2236 | 0.620 |
Why?
|
| Contraceptives, Oral, Hormonal | 2 | 2017 | 188 | 0.590 |
Why?
|
| Vulvar Neoplasms | 7 | 2018 | 272 | 0.590 |
Why?
|
| Vincristine | 7 | 2023 | 1036 | 0.580 |
Why?
|
| Genital Neoplasms, Female | 6 | 2013 | 516 | 0.580 |
Why?
|
| Hypothyroidism | 1 | 2022 | 659 | 0.570 |
Why?
|
| Gene Expression Regulation, Neoplastic | 26 | 2020 | 8425 | 0.570 |
Why?
|
| Cysts | 1 | 2022 | 676 | 0.570 |
Why?
|
| Hungary | 6 | 2016 | 84 | 0.560 |
Why?
|
| CA-125 Antigen | 8 | 2020 | 279 | 0.560 |
Why?
|
| Cystadenocarcinoma, Papillary | 10 | 2012 | 59 | 0.550 |
Why?
|
| Drug Substitution | 1 | 2019 | 281 | 0.550 |
Why?
|
| Neoplasms, Multiple Primary | 6 | 2017 | 600 | 0.550 |
Why?
|
| Adolescent | 61 | 2021 | 85649 | 0.550 |
Why?
|
| Adenocarcinoma, Mucinous | 13 | 2020 | 505 | 0.490 |
Why?
|
| Carcinoma in Situ | 7 | 2018 | 802 | 0.490 |
Why?
|
| Neoplasms, Cystic, Mucinous, and Serous | 4 | 2019 | 199 | 0.490 |
Why?
|
| Middle Aged | 139 | 2021 | 213127 | 0.480 |
Why?
|
| Risk Factors | 54 | 2023 | 72145 | 0.480 |
Why?
|
| Prognosis | 55 | 2020 | 29010 | 0.480 |
Why?
|
| DNA, Neoplasm | 18 | 2017 | 1758 | 0.480 |
Why?
|
| Matrix Metalloproteinases | 2 | 2011 | 391 | 0.470 |
Why?
|
| Immunohistochemistry | 30 | 2018 | 11363 | 0.460 |
Why?
|
| South America | 3 | 2020 | 181 | 0.460 |
Why?
|
| Carcinoma | 15 | 2019 | 2374 | 0.460 |
Why?
|
| Interferon Type I | 1 | 2017 | 542 | 0.450 |
Why?
|
| p21-Activated Kinases | 1 | 2013 | 128 | 0.440 |
Why?
|
| Tissue Inhibitor of Metalloproteinases | 2 | 2011 | 99 | 0.440 |
Why?
|
| Sialoglycoproteins | 5 | 2006 | 318 | 0.440 |
Why?
|
| Proto-Oncogene Proteins c-abl | 1 | 2013 | 146 | 0.430 |
Why?
|
| Endometriosis | 4 | 2016 | 834 | 0.410 |
Why?
|
| Loss of Heterozygosity | 15 | 2012 | 678 | 0.410 |
Why?
|
| Prenatal Diagnosis | 2 | 2018 | 1232 | 0.400 |
Why?
|
| Carboplatin | 10 | 2019 | 799 | 0.390 |
Why?
|
| Pre-Eclampsia | 4 | 2017 | 1196 | 0.380 |
Why?
|
| Abortion, Induced | 1 | 2017 | 458 | 0.380 |
Why?
|
| Genes, Tumor Suppressor | 9 | 2004 | 1097 | 0.370 |
Why?
|
| Metrorrhagia | 1 | 2010 | 16 | 0.370 |
Why?
|
| Neutrophils | 1 | 2022 | 3711 | 0.360 |
Why?
|
| Pregnancy, Multiple | 4 | 2017 | 217 | 0.360 |
Why?
|
| Stillbirth | 3 | 2021 | 346 | 0.350 |
Why?
|
| Ovarian Cysts | 5 | 2020 | 115 | 0.350 |
Why?
|
| Neoplasm, Residual | 6 | 2021 | 974 | 0.340 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2012 | 3502 | 0.340 |
Why?
|
| MicroRNAs | 7 | 2020 | 3731 | 0.330 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 1 | 2012 | 664 | 0.330 |
Why?
|
| Fertility | 3 | 2010 | 770 | 0.320 |
Why?
|
| Treatment Outcome | 32 | 2022 | 62966 | 0.310 |
Why?
|
| Gravidity | 3 | 2021 | 51 | 0.310 |
Why?
|
| RNA, Neoplasm | 6 | 2020 | 768 | 0.310 |
Why?
|
| Combined Modality Therapy | 20 | 2016 | 8621 | 0.310 |
Why?
|
| Risk | 15 | 2022 | 9679 | 0.300 |
Why?
|
| Gestational Age | 10 | 2021 | 3490 | 0.300 |
Why?
|
| Drug Administration Schedule | 10 | 2021 | 4929 | 0.290 |
Why?
|
| Ultrasonography, Prenatal | 6 | 2009 | 1694 | 0.290 |
Why?
|
| Lung Neoplasms | 7 | 2021 | 13019 | 0.290 |
Why?
|
| Chemotherapy, Adjuvant | 11 | 2021 | 3471 | 0.280 |
Why?
|
| Thoracotomy | 1 | 2008 | 363 | 0.280 |
Why?
|
| Neoplasm Metastasis | 18 | 2014 | 4839 | 0.280 |
Why?
|
| Antigens | 3 | 2008 | 1462 | 0.280 |
Why?
|
| Epithelial Cells | 12 | 2018 | 3678 | 0.270 |
Why?
|
| Health Services Accessibility | 1 | 2023 | 5133 | 0.270 |
Why?
|
| Immunity, Cellular | 4 | 2010 | 1606 | 0.270 |
Why?
|
| Isoenzymes | 4 | 2013 | 1725 | 0.270 |
Why?
|
| Abortion, Spontaneous | 4 | 2021 | 542 | 0.270 |
Why?
|
| Cell Transformation, Neoplastic | 7 | 2018 | 2940 | 0.270 |
Why?
|
| Papillomavirus Infections | 4 | 2021 | 1585 | 0.260 |
Why?
|
| Receptors, Estrogen | 1 | 2013 | 2186 | 0.260 |
Why?
|
| Apoptosis | 7 | 2020 | 9715 | 0.250 |
Why?
|
| Adenocarcinoma | 12 | 2019 | 6347 | 0.250 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 13 | 2015 | 3920 | 0.250 |
Why?
|
| Chorionic Villi | 4 | 2017 | 51 | 0.250 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2018 | 3014 | 0.250 |
Why?
|
| Carcinosarcoma | 2 | 2015 | 108 | 0.250 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 2008 | 804 | 0.250 |
Why?
|
| Tumor Cells, Cultured | 20 | 2020 | 6313 | 0.240 |
Why?
|
| Alcohol Oxidoreductases | 2 | 2016 | 170 | 0.240 |
Why?
|
| Microvessels | 1 | 2008 | 544 | 0.240 |
Why?
|
| Cell Line, Tumor | 18 | 2018 | 16665 | 0.240 |
Why?
|
| Chromosome Deletion | 7 | 2000 | 1400 | 0.240 |
Why?
|
| Overweight | 1 | 2015 | 2366 | 0.230 |
Why?
|
| Paget Disease, Extramammary | 2 | 2018 | 43 | 0.230 |
Why?
|
| Cisplatin | 7 | 2016 | 1637 | 0.230 |
Why?
|
| Carcinoma, Papillary | 4 | 2013 | 781 | 0.230 |
Why?
|
| Carcinoma, Squamous Cell | 7 | 2019 | 4029 | 0.230 |
Why?
|
| Cell Adhesion Molecules | 5 | 2016 | 1599 | 0.230 |
Why?
|
| Proto-Oncogenes | 1 | 2004 | 321 | 0.230 |
Why?
|
| Genes, p53 | 9 | 2010 | 755 | 0.230 |
Why?
|
| Cellular Structures | 1 | 2022 | 11 | 0.230 |
Why?
|
| RNA, Messenger | 23 | 2018 | 13029 | 0.220 |
Why?
|
| North America | 2 | 2017 | 1249 | 0.220 |
Why?
|
| Paclitaxel | 10 | 2016 | 1707 | 0.220 |
Why?
|
| Ploidies | 6 | 2010 | 281 | 0.220 |
Why?
|
| Antibiotics, Antineoplastic | 4 | 2020 | 692 | 0.220 |
Why?
|
| Neoplasm Invasiveness | 19 | 2018 | 3612 | 0.220 |
Why?
|
| Antigens, Neoplasm | 9 | 2013 | 1983 | 0.210 |
Why?
|
| Neoadjuvant Therapy | 8 | 2021 | 2721 | 0.210 |
Why?
|
| Aged | 77 | 2021 | 162944 | 0.210 |
Why?
|
| Registries | 8 | 2015 | 8077 | 0.210 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 3130 | 0.210 |
Why?
|
| Cross-Sectional Studies | 8 | 2023 | 24913 | 0.210 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 16 | 2016 | 4751 | 0.210 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 3236 | 0.210 |
Why?
|
| Sperm Injections, Intracytoplasmic | 1 | 2023 | 160 | 0.210 |
Why?
|
| Carcinoma, Endometrioid | 6 | 2014 | 271 | 0.210 |
Why?
|
| Growth Substances | 1 | 2004 | 783 | 0.200 |
Why?
|
| Fertilization | 1 | 2023 | 195 | 0.200 |
Why?
|
| Follow-Up Studies | 27 | 2020 | 39004 | 0.200 |
Why?
|
| Papillomaviridae | 4 | 2019 | 1118 | 0.200 |
Why?
|
| Blood Cell Count | 1 | 2022 | 402 | 0.200 |
Why?
|
| Lutein | 1 | 2022 | 125 | 0.200 |
Why?
|
| Live Birth | 2 | 2017 | 512 | 0.200 |
Why?
|
| Cervix Uteri | 3 | 2021 | 591 | 0.200 |
Why?
|
| Gynecology | 3 | 2016 | 509 | 0.200 |
Why?
|
| Genes, ras | 6 | 2001 | 691 | 0.200 |
Why?
|
| Tumor Virus Infections | 2 | 2002 | 451 | 0.200 |
Why?
|
| Telemedicine | 1 | 2018 | 2853 | 0.200 |
Why?
|
| Polymerase Chain Reaction | 23 | 2017 | 6171 | 0.200 |
Why?
|
| Neoplasm Proteins | 8 | 2006 | 3691 | 0.190 |
Why?
|
| Genes, BRCA1 | 5 | 2013 | 780 | 0.190 |
Why?
|
| Osteonectin | 2 | 2001 | 34 | 0.190 |
Why?
|
| Bleomycin | 4 | 2012 | 499 | 0.190 |
Why?
|
| HLA Antigens | 8 | 1986 | 1382 | 0.190 |
Why?
|
| Lymphocytes | 3 | 2022 | 2614 | 0.190 |
Why?
|
| Growth Differentiation Factor 2 | 1 | 2020 | 29 | 0.190 |
Why?
|
| Uterine Artery | 1 | 2020 | 36 | 0.190 |
Why?
|
| Semen | 1 | 2023 | 316 | 0.190 |
Why?
|
| Uterus | 5 | 2012 | 710 | 0.180 |
Why?
|
| Hysteroscopy | 1 | 2021 | 102 | 0.180 |
Why?
|
| Community Health Centers | 1 | 2023 | 428 | 0.180 |
Why?
|
| Disease-Free Survival | 12 | 2021 | 6891 | 0.180 |
Why?
|
| X-Rays | 1 | 2021 | 301 | 0.180 |
Why?
|
| Aged, 80 and over | 34 | 2021 | 57683 | 0.180 |
Why?
|
| Heat-Shock Proteins | 2 | 2004 | 822 | 0.180 |
Why?
|
| Treatment Refusal | 1 | 2003 | 416 | 0.180 |
Why?
|
| Mixed Tumor, Mullerian | 3 | 2004 | 56 | 0.180 |
Why?
|
| Survival Rate | 13 | 2020 | 12773 | 0.180 |
Why?
|
| Early Detection of Cancer | 3 | 2021 | 3070 | 0.180 |
Why?
|
| Genes, erbB-1 | 1 | 2000 | 161 | 0.170 |
Why?
|
| Arteriovenous Malformations | 1 | 2003 | 396 | 0.170 |
Why?
|
| Adaptor Proteins, Vesicular Transport | 2 | 1998 | 315 | 0.170 |
Why?
|
| Iodide Peroxidase | 1 | 2021 | 293 | 0.170 |
Why?
|
| Cyclin-Dependent Kinase 6 | 1 | 2022 | 322 | 0.170 |
Why?
|
| Angiopoietin-2 | 2 | 2012 | 170 | 0.170 |
Why?
|
| Cell Proliferation | 9 | 2020 | 10472 | 0.170 |
Why?
|
| Vitamin A | 2 | 2020 | 615 | 0.170 |
Why?
|
| Gene Expression Regulation, Enzymologic | 3 | 2021 | 1213 | 0.170 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-1 | 1 | 1999 | 149 | 0.170 |
Why?
|
| Infusions, Intravenous | 4 | 2017 | 2271 | 0.170 |
Why?
|
| Ostomy | 1 | 2019 | 27 | 0.170 |
Why?
|
| Fluorescent Antibody Technique | 12 | 2016 | 2505 | 0.170 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2008 | 2524 | 0.170 |
Why?
|
| Gene Expression Profiling | 13 | 2017 | 9410 | 0.170 |
Why?
|
| Predictive Value of Tests | 14 | 2017 | 15056 | 0.170 |
Why?
|
| Neovascularization, Pathologic | 2 | 2010 | 2633 | 0.170 |
Why?
|
| Tumor Suppressor Protein p53 | 9 | 2018 | 2948 | 0.170 |
Why?
|
| Contraceptive Devices, Female | 2 | 2017 | 43 | 0.170 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 3 | 2020 | 1434 | 0.170 |
Why?
|
| DNA Topoisomerases, Type I | 1 | 1999 | 102 | 0.170 |
Why?
|
| Time Factors | 23 | 2020 | 40054 | 0.160 |
Why?
|
| Cell Line | 13 | 2017 | 15994 | 0.160 |
Why?
|
| Organoids | 2 | 2018 | 692 | 0.160 |
Why?
|
| Endometrium | 3 | 1994 | 424 | 0.160 |
Why?
|
| BRCA1 Protein | 6 | 2013 | 1145 | 0.160 |
Why?
|
| Disease Progression | 7 | 2021 | 13256 | 0.160 |
Why?
|
| Antigens, Tumor-Associated, Carbohydrate | 3 | 1993 | 134 | 0.160 |
Why?
|
| Ovariectomy | 7 | 2013 | 660 | 0.160 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 2 | 2021 | 704 | 0.160 |
Why?
|
| Pregnancy, Tubal | 1 | 1998 | 16 | 0.160 |
Why?
|
| Mullerian Ducts | 2 | 2016 | 198 | 0.160 |
Why?
|
| Thyrotropin | 1 | 2022 | 850 | 0.160 |
Why?
|
| Age Factors | 12 | 2016 | 18355 | 0.160 |
Why?
|
| Diagnosis, Differential | 15 | 2020 | 12958 | 0.160 |
Why?
|
| Ganglioneuroma | 1 | 2018 | 57 | 0.160 |
Why?
|
| Medical Records | 6 | 2006 | 1413 | 0.160 |
Why?
|
| Alphapapillomavirus | 1 | 2021 | 221 | 0.160 |
Why?
|
| Neoplastic Syndromes, Hereditary | 2 | 2017 | 241 | 0.160 |
Why?
|
| Folic Acid Antagonists | 1 | 1998 | 82 | 0.150 |
Why?
|
| Ascitic Fluid | 1 | 2018 | 192 | 0.150 |
Why?
|
| Killer Cells, Natural | 6 | 2022 | 2133 | 0.150 |
Why?
|
| Chromosomes, Human, Pair 6 | 4 | 2001 | 380 | 0.150 |
Why?
|
| Precancerous Conditions | 4 | 2018 | 971 | 0.150 |
Why?
|
| Endometrial Hyperplasia | 2 | 1995 | 96 | 0.150 |
Why?
|
| Enterotoxins | 2 | 2010 | 368 | 0.150 |
Why?
|
| Cyclin A1 | 1 | 2016 | 11 | 0.150 |
Why?
|
| Brachytherapy | 3 | 2015 | 1246 | 0.150 |
Why?
|
| Organoplatinum Compounds | 3 | 2013 | 408 | 0.140 |
Why?
|
| Pulmonary Embolism | 3 | 2019 | 2370 | 0.140 |
Why?
|
| Antibodies, Monoclonal | 11 | 2017 | 9274 | 0.140 |
Why?
|
| DNA-Binding Proteins | 5 | 2016 | 9639 | 0.140 |
Why?
|
| Sensitivity and Specificity | 11 | 2021 | 14720 | 0.140 |
Why?
|
| Nuclear Proteins | 4 | 2016 | 5851 | 0.140 |
Why?
|
| Serum | 1 | 2017 | 212 | 0.140 |
Why?
|
| PTEN Phosphohydrolase | 2 | 2016 | 1144 | 0.140 |
Why?
|
| Gene Expression | 9 | 2016 | 7790 | 0.140 |
Why?
|
| Logistic Models | 5 | 2018 | 13403 | 0.140 |
Why?
|
| Obesity | 3 | 2015 | 12705 | 0.140 |
Why?
|
| Doxorubicin | 8 | 2020 | 2215 | 0.140 |
Why?
|
| Ascites | 1 | 2018 | 344 | 0.140 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 2 | 2017 | 890 | 0.130 |
Why?
|
| Incidence | 9 | 2016 | 20928 | 0.130 |
Why?
|
| Embolization, Therapeutic | 2 | 2003 | 1392 | 0.130 |
Why?
|
| Genetic Markers | 8 | 2020 | 2633 | 0.130 |
Why?
|
| Antibodies, Neoplasm | 2 | 2010 | 286 | 0.130 |
Why?
|
| Remote Consultation | 1 | 2018 | 238 | 0.130 |
Why?
|
| Case-Control Studies | 12 | 2020 | 21719 | 0.130 |
Why?
|
| Proto-Oncogene Proteins | 2 | 1998 | 4553 | 0.130 |
Why?
|
| Teratoma | 1 | 2018 | 387 | 0.130 |
Why?
|
| Sexual Partners | 1 | 1999 | 730 | 0.130 |
Why?
|
| Cloning, Molecular | 3 | 1999 | 4322 | 0.130 |
Why?
|
| Pregnancy Trimester, First | 4 | 2000 | 851 | 0.130 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2016 | 215 | 0.130 |
Why?
|
| Contraceptives, Oral | 4 | 2009 | 563 | 0.130 |
Why?
|
| Fetal Death | 1 | 2017 | 447 | 0.130 |
Why?
|
| Parity | 5 | 2016 | 929 | 0.130 |
Why?
|
| RNA Precursors | 1 | 2016 | 206 | 0.130 |
Why?
|
| Chromosomes, Human, Pair 17 | 5 | 1998 | 438 | 0.130 |
Why?
|
| Multivariate Analysis | 8 | 2020 | 12242 | 0.120 |
Why?
|
| Referral and Consultation | 4 | 2021 | 3527 | 0.120 |
Why?
|
| Ribonuclease III | 1 | 2016 | 275 | 0.120 |
Why?
|
| Neoplasms, Second Primary | 4 | 2008 | 1052 | 0.120 |
Why?
|
| Core Binding Factor beta Subunit | 1 | 2013 | 45 | 0.120 |
Why?
|
| High-Throughput Nucleotide Sequencing | 5 | 2020 | 3585 | 0.120 |
Why?
|
| Erythrocyte Transfusion | 1 | 2019 | 565 | 0.120 |
Why?
|
| Colectomy | 1 | 2019 | 681 | 0.120 |
Why?
|
| World Health Organization | 2 | 2016 | 1317 | 0.120 |
Why?
|
| T-Lymphocytes | 3 | 2008 | 10163 | 0.120 |
Why?
|
| DNA, Complementary | 7 | 2005 | 2049 | 0.120 |
Why?
|
| DEAD-box RNA Helicases | 1 | 2016 | 375 | 0.120 |
Why?
|
| Obstetrics | 2 | 2016 | 657 | 0.120 |
Why?
|
| Caspase 3 | 1 | 2016 | 759 | 0.120 |
Why?
|
| Laparoscopy | 6 | 2015 | 2121 | 0.110 |
Why?
|
| Antigen-Antibody Complex | 6 | 1986 | 517 | 0.110 |
Why?
|
| Kaplan-Meier Estimate | 5 | 2019 | 6534 | 0.110 |
Why?
|
| Oncogene Proteins, Viral | 1 | 1995 | 362 | 0.110 |
Why?
|
| DNA Helicases | 1 | 1999 | 861 | 0.110 |
Why?
|
| Brain Neoplasms | 7 | 2017 | 8829 | 0.110 |
Why?
|
| Adenine Nucleotide Translocator 2 | 1 | 2012 | 2 | 0.110 |
Why?
|
| Hydrops Fetalis | 1 | 2013 | 106 | 0.110 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2017 | 379 | 0.110 |
Why?
|
| Chromosomes, Human | 1 | 1995 | 457 | 0.110 |
Why?
|
| ATP-Binding Cassette Transporters | 2 | 2006 | 559 | 0.110 |
Why?
|
| Term Birth | 1 | 2013 | 135 | 0.110 |
Why?
|
| Hospitals, Special | 1 | 2013 | 101 | 0.110 |
Why?
|
| Sphingolipids | 1 | 2013 | 159 | 0.110 |
Why?
|
| Proportional Hazards Models | 5 | 2016 | 12344 | 0.110 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 9 | 2021 | 3862 | 0.110 |
Why?
|
| Antioxidants | 1 | 2020 | 1659 | 0.110 |
Why?
|
| DNA, Viral | 1 | 2019 | 2224 | 0.100 |
Why?
|
| Osteopontin | 5 | 2006 | 296 | 0.100 |
Why?
|
| Cell Death | 2 | 2015 | 1695 | 0.100 |
Why?
|
| Angiopoietin-1 | 1 | 2012 | 114 | 0.100 |
Why?
|
| Diseases in Twins | 1 | 1994 | 450 | 0.100 |
Why?
|
| Pelvic Neoplasms | 2 | 2020 | 254 | 0.100 |
Why?
|
| Aldehyde Dehydrogenase | 1 | 2012 | 142 | 0.100 |
Why?
|
| History, 21st Century | 1 | 2018 | 1533 | 0.100 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-3 | 1 | 2012 | 118 | 0.100 |
Why?
|
| Vitamins | 1 | 2020 | 1608 | 0.100 |
Why?
|
| Nerve Tissue Proteins | 2 | 2016 | 4465 | 0.100 |
Why?
|
| Clostridium perfringens | 2 | 2010 | 27 | 0.100 |
Why?
|
| Gene Deletion | 7 | 2004 | 2751 | 0.100 |
Why?
|
| In Situ Hybridization | 3 | 2010 | 1950 | 0.100 |
Why?
|
| Massachusetts | 5 | 2018 | 8662 | 0.100 |
Why?
|
| Postpartum Period | 1 | 1998 | 1078 | 0.100 |
Why?
|
| T-Lymphocytes, Cytotoxic | 2 | 2008 | 1820 | 0.100 |
Why?
|
| Cadherins | 1 | 2016 | 906 | 0.100 |
Why?
|
| Pregnancy Proteins | 1 | 2012 | 229 | 0.100 |
Why?
|
| Colposcopy | 2 | 2021 | 144 | 0.100 |
Why?
|
| Chromosomes, Human, Pair 5 | 3 | 2007 | 403 | 0.100 |
Why?
|
| Stromal Cells | 1 | 2016 | 1353 | 0.100 |
Why?
|
| Versicans | 1 | 2010 | 33 | 0.100 |
Why?
|
| Cell Division | 9 | 2001 | 4564 | 0.100 |
Why?
|
| Alleles | 13 | 2005 | 6931 | 0.090 |
Why?
|
| Epithelium | 7 | 2008 | 1680 | 0.090 |
Why?
|
| Polymorphism, Single-Stranded Conformational | 6 | 2001 | 335 | 0.090 |
Why?
|
| Cystadenocarcinoma | 5 | 1994 | 55 | 0.090 |
Why?
|
| New Hampshire | 1 | 2010 | 172 | 0.090 |
Why?
|
| Molecular Sequence Data | 13 | 2006 | 18112 | 0.090 |
Why?
|
| Survivors | 3 | 2007 | 2286 | 0.090 |
Why?
|
| Genes, BRCA2 | 1 | 2013 | 617 | 0.090 |
Why?
|
| Sinus Thrombosis, Intracranial | 1 | 2011 | 103 | 0.090 |
Why?
|
| Immunotherapy | 3 | 2023 | 4414 | 0.090 |
Why?
|
| Cell Count | 2 | 2010 | 1831 | 0.090 |
Why?
|
| History, 20th Century | 1 | 2018 | 2739 | 0.090 |
Why?
|
| Recurrence | 7 | 2019 | 8333 | 0.090 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2021 | 20086 | 0.090 |
Why?
|
| Cell Lineage | 1 | 2018 | 2504 | 0.090 |
Why?
|
| Mutation | 16 | 2018 | 29717 | 0.090 |
Why?
|
| Blood Transfusion | 1 | 2016 | 1296 | 0.090 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 2 | 2020 | 1038 | 0.090 |
Why?
|
| Menopause | 2 | 1994 | 1621 | 0.090 |
Why?
|
| Germ-Line Mutation | 3 | 2013 | 1786 | 0.090 |
Why?
|
| Cytotoxicity, Immunologic | 2 | 1992 | 1368 | 0.090 |
Why?
|
| Appendiceal Neoplasms | 2 | 2005 | 145 | 0.090 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2012 | 544 | 0.090 |
Why?
|
| Surgical Wound Infection | 1 | 2019 | 1538 | 0.090 |
Why?
|
| Biological Factors | 1 | 1990 | 164 | 0.080 |
Why?
|
| Oxidative Stress | 1 | 2020 | 3081 | 0.080 |
Why?
|
| Cytokines | 5 | 1998 | 7317 | 0.080 |
Why?
|
| DNA Repair | 1 | 2018 | 2042 | 0.080 |
Why?
|
| Gene Amplification | 5 | 2007 | 1062 | 0.080 |
Why?
|
| Li-Fraumeni Syndrome | 1 | 2010 | 114 | 0.080 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 1 | 2012 | 552 | 0.080 |
Why?
|
| Gene Dosage | 3 | 2016 | 1251 | 0.080 |
Why?
|
| Granulosa Cell Tumor | 1 | 2009 | 70 | 0.080 |
Why?
|
| Core Binding Factor Alpha 3 Subunit | 1 | 2008 | 56 | 0.080 |
Why?
|
| HLA-D Antigens | 1 | 2008 | 134 | 0.080 |
Why?
|
| Infusions, Parenteral | 2 | 2021 | 415 | 0.080 |
Why?
|
| Contractile Proteins | 1 | 2009 | 246 | 0.080 |
Why?
|
| Anesthetics | 1 | 2014 | 538 | 0.080 |
Why?
|
| Autoantibodies | 2 | 2010 | 2036 | 0.080 |
Why?
|
| Tight Junctions | 2 | 2010 | 310 | 0.080 |
Why?
|
| Uterine Cervical Dysplasia | 1 | 2012 | 385 | 0.080 |
Why?
|
| Child | 7 | 2018 | 77478 | 0.080 |
Why?
|
| Karyotyping | 5 | 1995 | 1243 | 0.080 |
Why?
|
| Fetal Diseases | 1 | 1994 | 903 | 0.080 |
Why?
|
| Protein Interaction Mapping | 1 | 2012 | 627 | 0.080 |
Why?
|
| Ultrasonography | 6 | 1997 | 5978 | 0.080 |
Why?
|
| Nucleic Acid Hybridization | 2 | 2007 | 1374 | 0.080 |
Why?
|
| Genomic Instability | 1 | 2012 | 695 | 0.080 |
Why?
|
| Academic Medical Centers | 2 | 2012 | 2749 | 0.080 |
Why?
|
| Embryo Implantation | 2 | 1996 | 272 | 0.080 |
Why?
|
| Receptors, Notch | 1 | 2012 | 739 | 0.080 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 2 | 1990 | 484 | 0.080 |
Why?
|
| Fibroblast Growth Factor 1 | 1 | 2007 | 54 | 0.080 |
Why?
|
| Cell Movement | 3 | 2016 | 5212 | 0.080 |
Why?
|
| Lymphocyte Culture Test, Mixed | 1 | 1988 | 517 | 0.080 |
Why?
|
| Lymphokines | 2 | 1988 | 949 | 0.080 |
Why?
|
| Salmon | 1 | 2007 | 36 | 0.070 |
Why?
|
| Transfection | 5 | 2015 | 5892 | 0.070 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2017 | 2938 | 0.070 |
Why?
|
| Postmenopause | 2 | 2004 | 2461 | 0.070 |
Why?
|
| Talc | 1 | 2007 | 47 | 0.070 |
Why?
|
| Deoxycytidine | 2 | 2018 | 824 | 0.070 |
Why?
|
| Immunoenzyme Techniques | 5 | 2001 | 1799 | 0.070 |
Why?
|
| Up-Regulation | 8 | 2010 | 4211 | 0.070 |
Why?
|
| Dissection | 3 | 2003 | 294 | 0.070 |
Why?
|
| Proteins | 3 | 1999 | 6096 | 0.070 |
Why?
|
| Hydatidiform Mole, Invasive | 3 | 1998 | 4 | 0.070 |
Why?
|
| Risk Assessment | 7 | 2021 | 23320 | 0.070 |
Why?
|
| Selenium-Binding Proteins | 1 | 2006 | 14 | 0.070 |
Why?
|
| X Chromosome | 4 | 1998 | 815 | 0.070 |
Why?
|
| Pluripotent Stem Cells | 1 | 2014 | 795 | 0.070 |
Why?
|
| Insurance Coverage | 1 | 2018 | 1895 | 0.070 |
Why?
|
| Apoptosis Regulatory Proteins | 4 | 2016 | 1158 | 0.070 |
Why?
|
| Protein Kinases | 1 | 2014 | 1638 | 0.070 |
Why?
|
| Eosinophil-Derived Neurotoxin | 1 | 2006 | 13 | 0.070 |
Why?
|
| Prospective Studies | 6 | 2022 | 53187 | 0.070 |
Why?
|
| Decidua | 2 | 2022 | 86 | 0.070 |
Why?
|
| Venous Thromboembolism | 1 | 2019 | 1668 | 0.070 |
Why?
|
| Myometrium | 1 | 2007 | 181 | 0.070 |
Why?
|
| Hong Kong | 2 | 2017 | 148 | 0.070 |
Why?
|
| United States | 6 | 2021 | 69693 | 0.070 |
Why?
|
| Alkaline Phosphatase | 2 | 1986 | 865 | 0.070 |
Why?
|
| Granzymes | 1 | 2007 | 270 | 0.070 |
Why?
|
| Base Sequence | 9 | 2000 | 12797 | 0.070 |
Why?
|
| Radioimmunoassay | 6 | 1994 | 918 | 0.070 |
Why?
|
| Infant, Newborn | 3 | 2022 | 25575 | 0.070 |
Why?
|
| Heterozygote | 6 | 2005 | 2790 | 0.070 |
Why?
|
| Mitochondrial Proteins | 1 | 2012 | 995 | 0.070 |
Why?
|
| Sequence Homology, Amino Acid | 3 | 2000 | 2837 | 0.070 |
Why?
|
| DNA Mutational Analysis | 6 | 2017 | 4187 | 0.070 |
Why?
|
| Down-Regulation | 3 | 2003 | 3001 | 0.070 |
Why?
|
| Cell Survival | 6 | 2016 | 5872 | 0.070 |
Why?
|
| Leukocytes, Mononuclear | 1 | 1992 | 1835 | 0.070 |
Why?
|
| Neoplastic Stem Cells | 2 | 2012 | 1376 | 0.070 |
Why?
|
| Insurance, Health | 1 | 2018 | 2493 | 0.070 |
Why?
|
| Lymph Nodes | 4 | 2007 | 3465 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 7 | 2 | 1997 | 321 | 0.070 |
Why?
|
| Cytoplasm | 4 | 2008 | 1539 | 0.070 |
Why?
|
| Membrane Proteins | 3 | 2020 | 7873 | 0.070 |
Why?
|
| Preoperative Care | 2 | 2010 | 2245 | 0.070 |
Why?
|
| Lasers | 3 | 2004 | 952 | 0.060 |
Why?
|
| Feasibility Studies | 4 | 2021 | 5062 | 0.060 |
Why?
|
| Immune Sera | 2 | 1983 | 641 | 0.060 |
Why?
|
| Radiotherapy, Adjuvant | 3 | 2015 | 1769 | 0.060 |
Why?
|
| Histocompatibility Antigens | 1 | 1986 | 471 | 0.060 |
Why?
|
| Signal Transduction | 5 | 2015 | 23387 | 0.060 |
Why?
|
| Cystadenocarcinoma, Mucinous | 2 | 2005 | 49 | 0.060 |
Why?
|
| Tumor Suppressor Proteins | 4 | 2006 | 2842 | 0.060 |
Why?
|
| Premature Birth | 1 | 2017 | 1713 | 0.060 |
Why?
|
| Chromosomes, Human, Pair 3 | 2 | 1996 | 323 | 0.060 |
Why?
|
| Peptide Fragments | 6 | 2007 | 5095 | 0.060 |
Why?
|
| Mucin-1 | 2 | 2009 | 543 | 0.060 |
Why?
|
| BRCA2 Protein | 2 | 2007 | 790 | 0.060 |
Why?
|
| Vagina | 3 | 2015 | 825 | 0.060 |
Why?
|
| T-Lymphocytes, Regulatory | 2 | 2008 | 2986 | 0.060 |
Why?
|
| Tissue Array Analysis | 2 | 2016 | 553 | 0.060 |
Why?
|
| Glycolipids | 1 | 1985 | 205 | 0.060 |
Why?
|
| Pregnadienediols | 1 | 2003 | 9 | 0.060 |
Why?
|
| Co-Repressor Proteins | 2 | 2016 | 194 | 0.060 |
Why?
|
| Blotting, Northern | 3 | 1994 | 1581 | 0.060 |
Why?
|
| Salvage Therapy | 1 | 2010 | 1269 | 0.060 |
Why?
|
| Quality of Life | 6 | 2005 | 12730 | 0.060 |
Why?
|
| Body Mass Index | 4 | 2016 | 12695 | 0.060 |
Why?
|
| Developing Countries | 1 | 2016 | 2789 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2007 | 578 | 0.060 |
Why?
|
| Amino Acid Sequence | 6 | 2006 | 13814 | 0.060 |
Why?
|
| Anemia | 2 | 2012 | 1499 | 0.060 |
Why?
|
| Gene Expression Regulation | 2 | 2014 | 12071 | 0.060 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2013 | 2038 | 0.060 |
Why?
|
| Cell Adhesion | 3 | 2016 | 3139 | 0.060 |
Why?
|
| Y Chromosome | 2 | 1995 | 206 | 0.060 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2007 | 627 | 0.060 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 3 | 2005 | 647 | 0.060 |
Why?
|
| Micromanipulation | 1 | 2003 | 53 | 0.060 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2011 | 895 | 0.060 |
Why?
|
| Cyclin E | 1 | 2004 | 172 | 0.060 |
Why?
|
| Population Surveillance | 1 | 1994 | 2616 | 0.060 |
Why?
|
| Xenograft Model Antitumor Assays | 3 | 2020 | 3557 | 0.060 |
Why?
|
| Family Therapy | 5 | 1990 | 207 | 0.060 |
Why?
|
| Marriage | 4 | 2003 | 338 | 0.060 |
Why?
|
| Lymph Node Excision | 3 | 2015 | 1248 | 0.060 |
Why?
|
| Mass Screening | 2 | 2001 | 5238 | 0.050 |
Why?
|
| Kallikreins | 1 | 2004 | 258 | 0.050 |
Why?
|
| Intraoperative Complications | 3 | 2007 | 1188 | 0.050 |
Why?
|
| Quality Indicators, Health Care | 1 | 2013 | 1831 | 0.050 |
Why?
|
| Creatine Kinase | 1 | 2005 | 694 | 0.050 |
Why?
|
| Intensive Care Units | 1 | 2016 | 3679 | 0.050 |
Why?
|
| Abortion, Missed | 3 | 1994 | 11 | 0.050 |
Why?
|
| Budesonide | 1 | 2003 | 154 | 0.050 |
Why?
|
| Microsatellite Repeats | 6 | 2001 | 800 | 0.050 |
Why?
|
| Transcription Factors | 5 | 2002 | 12164 | 0.050 |
Why?
|
| Lymphatic Metastasis | 5 | 2015 | 2906 | 0.050 |
Why?
|
| Patient Discharge | 1 | 2015 | 3300 | 0.050 |
Why?
|
| Steroid 17-alpha-Hydroxylase | 1 | 2002 | 98 | 0.050 |
Why?
|
| Haptoglobins | 1 | 2003 | 165 | 0.050 |
Why?
|
| Point Mutation | 2 | 2000 | 1624 | 0.050 |
Why?
|
| Interleukin-6 | 1 | 2012 | 3199 | 0.050 |
Why?
|
| Propionibacterium acnes | 2 | 1983 | 66 | 0.050 |
Why?
|
| Leukocytes | 1 | 1990 | 2039 | 0.050 |
Why?
|
| DNA Methylation | 4 | 2017 | 4282 | 0.050 |
Why?
|
| Polyploidy | 1 | 2002 | 114 | 0.050 |
Why?
|
| Cholecalciferol | 1 | 2007 | 537 | 0.050 |
Why?
|
| Antigens, CD | 2 | 2013 | 4024 | 0.050 |
Why?
|
| Survival Analysis | 7 | 2012 | 10248 | 0.050 |
Why?
|
| Dissociative Disorders | 2 | 1994 | 231 | 0.050 |
Why?
|
| Glycoproteins | 1 | 2009 | 2260 | 0.050 |
Why?
|
| Animals | 19 | 2022 | 168561 | 0.050 |
Why?
|
| Piperazines | 2 | 2013 | 2488 | 0.050 |
Why?
|
| Cell Differentiation | 3 | 2014 | 11470 | 0.050 |
Why?
|
| Tumor Necrosis Factor-alpha | 3 | 2009 | 4414 | 0.050 |
Why?
|
| Turner Syndrome | 1 | 1982 | 130 | 0.050 |
Why?
|
| Spermatozoa | 1 | 1985 | 625 | 0.050 |
Why?
|
| Medical Oncology | 1 | 2013 | 2235 | 0.050 |
Why?
|
| CHO Cells | 2 | 2010 | 1407 | 0.050 |
Why?
|
| Adenosine Triphosphate | 1 | 2007 | 2024 | 0.050 |
Why?
|
| Blotting, Western | 5 | 2010 | 5180 | 0.050 |
Why?
|
| Radiotherapy, High-Energy | 2 | 2000 | 228 | 0.050 |
Why?
|
| Puerperal Disorders | 1 | 1984 | 275 | 0.050 |
Why?
|
| Flow Cytometry | 6 | 2010 | 5975 | 0.050 |
Why?
|
| Cystadenoma | 2 | 2000 | 84 | 0.050 |
Why?
|
| Abortion, Incomplete | 2 | 1994 | 13 | 0.050 |
Why?
|
| Genital Diseases, Female | 2 | 2001 | 197 | 0.050 |
Why?
|
| Infant | 1 | 2023 | 35070 | 0.050 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2020 | 4438 | 0.050 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2006 | 789 | 0.050 |
Why?
|
| Mice | 12 | 2022 | 81045 | 0.050 |
Why?
|
| Estradiol | 5 | 1994 | 2021 | 0.050 |
Why?
|
| Liver Neoplasms | 3 | 2011 | 4249 | 0.050 |
Why?
|
| Catechol O-Methyltransferase | 1 | 2002 | 245 | 0.050 |
Why?
|
| Psychotherapy, Group | 3 | 1990 | 407 | 0.050 |
Why?
|
| Mitoxantrone | 1 | 2020 | 149 | 0.050 |
Why?
|
| Forkhead Transcription Factors | 1 | 2007 | 1613 | 0.050 |
Why?
|
| Human Genome Project | 1 | 2000 | 192 | 0.040 |
Why?
|
| Pandemics | 1 | 2020 | 8328 | 0.040 |
Why?
|
| Protein Biosynthesis | 4 | 2006 | 2126 | 0.040 |
Why?
|
| Embolism, Amniotic Fluid | 1 | 1999 | 19 | 0.040 |
Why?
|
| Epigenesis, Genetic | 1 | 2013 | 3639 | 0.040 |
Why?
|
| Electrocoagulation | 1 | 2020 | 158 | 0.040 |
Why?
|
| Selenoproteins | 1 | 2021 | 216 | 0.040 |
Why?
|
| Adnexa Uteri | 1 | 2019 | 45 | 0.040 |
Why?
|
| Cardiac Output, Low | 1 | 2000 | 193 | 0.040 |
Why?
|
| Promoter Regions, Genetic | 2 | 2013 | 5867 | 0.040 |
Why?
|
| Observer Variation | 3 | 2019 | 2593 | 0.040 |
Why?
|
| Receptor, erbB-3 | 1 | 2000 | 142 | 0.040 |
Why?
|
| Lymphocyte Activation | 2 | 2007 | 5519 | 0.040 |
Why?
|
| Indoles | 1 | 2007 | 1834 | 0.040 |
Why?
|
| Information Services | 1 | 2000 | 244 | 0.040 |
Why?
|
| Cytogenetics | 2 | 1992 | 203 | 0.040 |
Why?
|
| RecQ Helicases | 1 | 1999 | 54 | 0.040 |
Why?
|
| Papillomavirus E7 Proteins | 1 | 2019 | 123 | 0.040 |
Why?
|
| Suction | 1 | 2020 | 267 | 0.040 |
Why?
|
| Cells, Cultured | 8 | 2010 | 19223 | 0.040 |
Why?
|
| Topotecan | 3 | 2004 | 138 | 0.040 |
Why?
|
| Anti-Asthmatic Agents | 1 | 2003 | 533 | 0.040 |
Why?
|
| Cell Growth Processes | 2 | 2010 | 400 | 0.040 |
Why?
|
| Patient Readmission | 1 | 2013 | 3111 | 0.040 |
Why?
|
| Biological Products | 1 | 1988 | 856 | 0.040 |
Why?
|
| Practice Guidelines as Topic | 2 | 2009 | 7276 | 0.040 |
Why?
|
| RNA, Untranslated | 1 | 2002 | 454 | 0.040 |
Why?
|
| Gene Knockdown Techniques | 2 | 2013 | 1655 | 0.040 |
Why?
|
| Cyclin-Dependent Kinase 4 | 1 | 2022 | 535 | 0.040 |
Why?
|
| Chickens | 1 | 2020 | 865 | 0.040 |
Why?
|
| Uterine Perforation | 1 | 2018 | 6 | 0.040 |
Why?
|
| Infertility, Female | 1 | 2005 | 784 | 0.040 |
Why?
|
| Interferon-gamma | 2 | 1993 | 3199 | 0.040 |
Why?
|
| Online Systems | 1 | 2019 | 184 | 0.040 |
Why?
|
| Cytarabine | 1 | 2020 | 684 | 0.040 |
Why?
|
| Omentum | 1 | 2019 | 170 | 0.040 |
Why?
|
| Human papillomavirus 18 | 1 | 2019 | 128 | 0.040 |
Why?
|
| Genetic Complementation Test | 1 | 1999 | 561 | 0.040 |
Why?
|
| Sulfonamides | 1 | 2007 | 1932 | 0.040 |
Why?
|
| Carotenoids | 2 | 1995 | 624 | 0.040 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 3 | 2006 | 503 | 0.040 |
Why?
|
| Receptor, Macrophage Colony-Stimulating Factor | 1 | 1998 | 87 | 0.040 |
Why?
|
| Adaptation, Psychological | 2 | 2007 | 2575 | 0.040 |
Why?
|
| Spinal Puncture | 1 | 2000 | 281 | 0.040 |
Why?
|
| Delivery of Health Care | 1 | 2016 | 5304 | 0.040 |
Why?
|
| Male | 24 | 2023 | 349538 | 0.040 |
Why?
|
| Gene Regulatory Networks | 2 | 2017 | 1707 | 0.040 |
Why?
|
| Mice, Nude | 2 | 2012 | 3689 | 0.040 |
Why?
|
| Radiography, Thoracic | 1 | 2004 | 1265 | 0.040 |
Why?
|
| Congresses as Topic | 1 | 2002 | 764 | 0.040 |
Why?
|
| Saudi Arabia | 1 | 1998 | 209 | 0.040 |
Why?
|
| RNA Interference | 2 | 2017 | 2890 | 0.040 |
Why?
|
| Antineoplastic Agents, Phytogenic | 2 | 2002 | 623 | 0.040 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 2 | 1997 | 799 | 0.040 |
Why?
|
| Radiography | 2 | 2007 | 7010 | 0.040 |
Why?
|
| Drug Therapy, Combination | 6 | 1984 | 6483 | 0.040 |
Why?
|
| Vaginal Neoplasms | 1 | 1978 | 106 | 0.040 |
Why?
|
| Colorectal Neoplasms | 1 | 2017 | 6754 | 0.040 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2003 | 783 | 0.040 |
Why?
|
| Immunophenotyping | 2 | 2013 | 1866 | 0.040 |
Why?
|
| Genome | 1 | 2005 | 1803 | 0.040 |
Why?
|
| Human papillomavirus 16 | 1 | 2019 | 262 | 0.040 |
Why?
|
| Odds Ratio | 3 | 2006 | 9846 | 0.040 |
Why?
|
| Phenotype | 4 | 2018 | 16331 | 0.040 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 1998 | 363 | 0.040 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2000 | 638 | 0.040 |
Why?
|
| Fenfluramine | 1 | 1996 | 60 | 0.040 |
Why?
|
| Contraception | 2 | 1995 | 356 | 0.040 |
Why?
|
| Postpartum Hemorrhage | 1 | 1980 | 258 | 0.040 |
Why?
|
| Vulva | 2 | 2008 | 87 | 0.040 |
Why?
|
| Patient Compliance | 3 | 2004 | 2680 | 0.040 |
Why?
|
| Organ Specificity | 2 | 2017 | 2003 | 0.040 |
Why?
|
| Postoperative Complications | 5 | 2021 | 15244 | 0.030 |
Why?
|
| Area Under Curve | 1 | 2020 | 1653 | 0.030 |
Why?
|
| Appetite Depressants | 1 | 1996 | 110 | 0.030 |
Why?
|
| Organ Culture Techniques | 1 | 2018 | 808 | 0.030 |
Why?
|
| Serine Endopeptidases | 1 | 2001 | 1073 | 0.030 |
Why?
|
| Diet | 3 | 2007 | 7923 | 0.030 |
Why?
|
| Dietary Proteins | 2 | 1995 | 963 | 0.030 |
Why?
|
| Exons | 3 | 2000 | 2431 | 0.030 |
Why?
|
| Cell Line, Transformed | 2 | 2013 | 898 | 0.030 |
Why?
|
| Twins | 2 | 1995 | 339 | 0.030 |
Why?
|
| DNA Copy Number Variations | 2 | 2016 | 1940 | 0.030 |
Why?
|
| DNA Probes | 3 | 2010 | 560 | 0.030 |
Why?
|
| Pelvis | 1 | 1980 | 730 | 0.030 |
Why?
|
| Lymphoma | 1 | 2005 | 1873 | 0.030 |
Why?
|
| Genetic Predisposition to Disease | 4 | 2018 | 17400 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 11 | 1 | 1997 | 417 | 0.030 |
Why?
|
| Lost to Follow-Up | 1 | 2016 | 105 | 0.030 |
Why?
|
| Capsid Proteins | 1 | 2019 | 479 | 0.030 |
Why?
|
| Histones | 1 | 2006 | 2597 | 0.030 |
Why?
|
| In Situ Nick-End Labeling | 2 | 2010 | 643 | 0.030 |
Why?
|
| Cyclins | 1 | 1998 | 601 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 1 | 1998 | 380 | 0.030 |
Why?
|
| Transglutaminases | 1 | 2016 | 194 | 0.030 |
Why?
|
| Cell Culture Techniques | 2 | 2016 | 1670 | 0.030 |
Why?
|
| Receptors, Cell Surface | 1 | 1985 | 2867 | 0.030 |
Why?
|
| Demography | 1 | 2020 | 1650 | 0.030 |
Why?
|
| Receptors, Androgen | 2 | 1998 | 1057 | 0.030 |
Why?
|
| Enzyme Inhibitors | 1 | 2006 | 3800 | 0.030 |
Why?
|
| Sexual Behavior | 4 | 2005 | 2050 | 0.030 |
Why?
|
| Centromere | 1 | 1996 | 220 | 0.030 |
Why?
|
| Etanidazole | 1 | 1994 | 26 | 0.030 |
Why?
|
| Glycosylation | 2 | 2010 | 1123 | 0.030 |
Why?
|
| Mutagenesis | 1 | 1999 | 1263 | 0.030 |
Why?
|
| Pseudomyxoma Peritonei | 1 | 1994 | 20 | 0.030 |
Why?
|
| Intermediate Filaments | 1 | 1995 | 175 | 0.030 |
Why?
|
| Cell Cycle | 2 | 2013 | 2964 | 0.030 |
Why?
|
| Robotics | 2 | 2015 | 892 | 0.030 |
Why?
|
| Tissue Distribution | 1 | 1999 | 2335 | 0.030 |
Why?
|
| HeLa Cells | 1 | 2021 | 3127 | 0.030 |
Why?
|
| Menstruation Disturbances | 1 | 1995 | 148 | 0.030 |
Why?
|
| Abortion, Therapeutic | 1 | 1994 | 35 | 0.030 |
Why?
|
| Length of Stay | 2 | 2021 | 6294 | 0.030 |
Why?
|
| Bulimia | 1 | 1996 | 381 | 0.030 |
Why?
|
| Thecoma | 1 | 1994 | 11 | 0.030 |
Why?
|
| Vacuum Extraction, Obstetrical | 1 | 1994 | 15 | 0.030 |
Why?
|
| Lactosylceramides | 1 | 2013 | 15 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2002 | 3913 | 0.030 |
Why?
|
| Precipitin Tests | 2 | 1985 | 829 | 0.030 |
Why?
|
| Jews | 1 | 1996 | 385 | 0.030 |
Why?
|
| Retinoblastoma Protein | 1 | 1998 | 701 | 0.030 |
Why?
|
| Frameshift Mutation | 1 | 1996 | 399 | 0.030 |
Why?
|
| Transforming Growth Factor alpha | 1 | 1994 | 135 | 0.030 |
Why?
|
| Triage | 1 | 2021 | 977 | 0.030 |
Why?
|
| DNA Fingerprinting | 1 | 1994 | 112 | 0.030 |
Why?
|
| Agranulocytosis | 2 | 1984 | 100 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 4 | 1 | 1995 | 374 | 0.030 |
Why?
|
| Medroxyprogesterone Acetate | 1 | 1994 | 162 | 0.030 |
Why?
|
| Taxoids | 2 | 2012 | 665 | 0.030 |
Why?
|
| Cell Transformation, Viral | 1 | 1995 | 565 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 9 | 1 | 1995 | 537 | 0.030 |
Why?
|
| Blotting, Southern | 3 | 2004 | 803 | 0.030 |
Why?
|
| Transcriptional Activation | 1 | 2000 | 1782 | 0.030 |
Why?
|
| Oxygen Consumption | 1 | 2000 | 1869 | 0.030 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2003 | 1788 | 0.030 |
Why?
|
| Iodine Radioisotopes | 1 | 1997 | 1030 | 0.030 |
Why?
|
| Killer Cells, Lymphokine-Activated | 1 | 1992 | 42 | 0.030 |
Why?
|
| Biopsy, Needle | 1 | 1978 | 1640 | 0.030 |
Why?
|
| Protein Tyrosine Phosphatases | 1 | 1995 | 473 | 0.030 |
Why?
|
| Social Support | 4 | 2005 | 2117 | 0.030 |
Why?
|
| Metalloendopeptidases | 1 | 1994 | 396 | 0.030 |
Why?
|
| Genes, myc | 1 | 1994 | 399 | 0.030 |
Why?
|
| Glycoprotein Hormones, alpha Subunit | 2 | 1989 | 98 | 0.030 |
Why?
|
| Polymorphism, Genetic | 3 | 2002 | 4328 | 0.030 |
Why?
|
| Clinical Enzyme Tests | 1 | 2012 | 115 | 0.030 |
Why?
|
| Caffeine | 1 | 1997 | 699 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 1995 | 657 | 0.030 |
Why?
|
| Pyrazines | 1 | 2018 | 1231 | 0.030 |
Why?
|
| Family Health | 2 | 2009 | 1282 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 1998 | 987 | 0.030 |
Why?
|
| Proteomics | 2 | 2022 | 3618 | 0.030 |
Why?
|
| Mandatory Reporting | 1 | 2013 | 121 | 0.030 |
Why?
|
| Regression Analysis | 3 | 2007 | 6452 | 0.030 |
Why?
|
| Molecular Probes | 1 | 1994 | 316 | 0.030 |
Why?
|
| GTP-Binding Proteins | 1 | 2016 | 970 | 0.030 |
Why?
|
| Chromosome Mapping | 5 | 2000 | 4742 | 0.030 |
Why?
|
| Confidence Intervals | 1 | 1998 | 2970 | 0.030 |
Why?
|
| Receptor, erbB-2 | 2 | 2001 | 2410 | 0.030 |
Why?
|
| Fluorouracil | 1 | 2016 | 1615 | 0.030 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2016 | 713 | 0.030 |
Why?
|
| DNA Replication | 1 | 2018 | 1397 | 0.030 |
Why?
|
| Core Binding Factor Alpha 2 Subunit | 1 | 2013 | 345 | 0.020 |
Why?
|
| Biopsy | 3 | 2008 | 6756 | 0.020 |
Why?
|
| Progesterone | 2 | 1994 | 773 | 0.020 |
Why?
|
| Polymorphism, Restriction Fragment Length | 1 | 1992 | 768 | 0.020 |
Why?
|
| Cricetinae | 2 | 2010 | 2471 | 0.020 |
Why?
|
| Somatoform Disorders | 1 | 1994 | 423 | 0.020 |
Why?
|
| Dosage Compensation, Genetic | 3 | 1998 | 211 | 0.020 |
Why?
|
| Tumor Burden | 1 | 2017 | 1905 | 0.020 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2013 | 441 | 0.020 |
Why?
|
| Transcription, Genetic | 4 | 2004 | 7721 | 0.020 |
Why?
|
| DNA Damage | 2 | 2012 | 2423 | 0.020 |
Why?
|
| Perioperative Care | 1 | 2019 | 997 | 0.020 |
Why?
|
| Codon | 1 | 1993 | 611 | 0.020 |
Why?
|
| Specialization | 1 | 2016 | 777 | 0.020 |
Why?
|
| Cranial Irradiation | 1 | 1994 | 401 | 0.020 |
Why?
|
| Stress, Psychological | 5 | 2004 | 4229 | 0.020 |
Why?
|
| Positron-Emission Tomography | 1 | 2007 | 6259 | 0.020 |
Why?
|
| Genotype | 1 | 2005 | 12946 | 0.020 |
Why?
|
| Schizophrenia | 5 | 1990 | 6874 | 0.020 |
Why?
|
| Splenectomy | 1 | 1992 | 395 | 0.020 |
Why?
|
| Neoplasms | 3 | 2015 | 21596 | 0.020 |
Why?
|
| Phthalazines | 1 | 2013 | 361 | 0.020 |
Why?
|
| Methionine | 1 | 2013 | 590 | 0.020 |
Why?
|
| Fluoxetine | 1 | 1994 | 749 | 0.020 |
Why?
|
| Adaptor Proteins, Signal Transducing | 2 | 1998 | 2915 | 0.020 |
Why?
|
| Immune Tolerance | 2 | 1992 | 2257 | 0.020 |
Why?
|
| Personality Inventory | 3 | 2005 | 1026 | 0.020 |
Why?
|
| Alternative Splicing | 1 | 2016 | 1118 | 0.020 |
Why?
|
| Spheroids, Cellular | 1 | 2012 | 351 | 0.020 |
Why?
|
| Thrombocytopenia | 3 | 2000 | 1171 | 0.020 |
Why?
|
| Home Nursing | 1 | 1990 | 92 | 0.020 |
Why?
|
| Triplets | 1 | 1990 | 43 | 0.020 |
Why?
|
| Office Visits | 1 | 1994 | 598 | 0.020 |
Why?
|
| Recombinant Fusion Proteins | 1 | 1999 | 3770 | 0.020 |
Why?
|
| Vaccination | 1 | 2002 | 3256 | 0.020 |
Why?
|
| Menstrual Cycle | 1 | 1993 | 551 | 0.020 |
Why?
|
| Viral Load | 1 | 2019 | 3292 | 0.020 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2015 | 689 | 0.020 |
Why?
|
| Gene Transfer Techniques | 1 | 1995 | 1224 | 0.020 |
Why?
|
| Ubiquitin-Protein Ligase Complexes | 1 | 2010 | 168 | 0.020 |
Why?
|
| Intestines | 1 | 2019 | 1923 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 10 | 1 | 2010 | 287 | 0.020 |
Why?
|
| Gravitation | 1 | 2009 | 82 | 0.020 |
Why?
|
| Melanoma | 1 | 2008 | 5462 | 0.020 |
Why?
|
| Cytogenetic Analysis | 1 | 2010 | 295 | 0.020 |
Why?
|
| Saccharomyces cerevisiae Proteins | 1 | 1999 | 1884 | 0.020 |
Why?
|
| Estrogens | 3 | 2002 | 1562 | 0.020 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 2 | 2016 | 2906 | 0.020 |
Why?
|
| Antibody Formation | 2 | 1984 | 1402 | 0.020 |
Why?
|
| Disease Models, Animal | 2 | 2020 | 18006 | 0.020 |
Why?
|
| Reference Values | 2 | 2000 | 4982 | 0.020 |
Why?
|
| Cricetulus | 1 | 2010 | 817 | 0.020 |
Why?
|
| Microscopy, Fluorescence | 1 | 2016 | 2699 | 0.020 |
Why?
|
| Obstetric Labor, Premature | 1 | 1990 | 279 | 0.020 |
Why?
|
| Folic Acid | 1 | 2015 | 1300 | 0.020 |
Why?
|
| Monokines | 1 | 1988 | 75 | 0.020 |
Why?
|
| Receptors, Laminin | 1 | 2007 | 26 | 0.020 |
Why?
|
| Concanavalin A | 1 | 1988 | 191 | 0.020 |
Why?
|
| Pyrazoles | 1 | 2018 | 1970 | 0.020 |
Why?
|
| Cell Membrane | 1 | 1998 | 3744 | 0.020 |
Why?
|
| Electron Probe Microanalysis | 1 | 2007 | 33 | 0.020 |
Why?
|
| Somatomedins | 1 | 1988 | 192 | 0.020 |
Why?
|
| Fee-for-Service Plans | 1 | 2013 | 694 | 0.020 |
Why?
|
| Clinical Trials as Topic | 4 | 2000 | 7901 | 0.020 |
Why?
|
| Saccharomyces cerevisiae | 1 | 1999 | 2749 | 0.020 |
Why?
|
| Pregnancy Trimester, Second | 2 | 2008 | 732 | 0.020 |
Why?
|
| Aftercare | 1 | 1994 | 860 | 0.020 |
Why?
|
| Colony-Stimulating Factors | 1 | 1988 | 216 | 0.020 |
Why?
|
| Recombinant Proteins | 2 | 2009 | 6608 | 0.020 |
Why?
|
| Phosphoproteins | 1 | 2016 | 2440 | 0.020 |
Why?
|
| Microscopy, Polarization | 1 | 2007 | 87 | 0.020 |
Why?
|
| Abdomen | 1 | 2013 | 1107 | 0.020 |
Why?
|
| Transforming Growth Factor beta | 1 | 1995 | 2006 | 0.020 |
Why?
|
| Vinblastine | 2 | 1989 | 490 | 0.020 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2009 | 713 | 0.020 |
Why?
|
| Life Change Events | 4 | 1994 | 937 | 0.020 |
Why?
|
| GPI-Linked Proteins | 1 | 2008 | 434 | 0.020 |
Why?
|
| Second-Look Surgery | 1 | 2006 | 29 | 0.020 |
Why?
|
| Receptors, Fibroblast Growth Factor | 1 | 2007 | 185 | 0.020 |
Why?
|
| Radiotherapy Dosage | 1 | 2013 | 2876 | 0.020 |
Why?
|
| Postoperative Period | 2 | 2001 | 1839 | 0.020 |
Why?
|
| Emotions | 4 | 2003 | 2657 | 0.020 |
Why?
|
| Nephelometry and Turbidimetry | 2 | 1983 | 91 | 0.020 |
Why?
|
| Costs and Cost Analysis | 1 | 2012 | 1679 | 0.020 |
Why?
|
| Quality Improvement | 1 | 2021 | 3738 | 0.020 |
Why?
|
| Sarcoma | 1 | 1978 | 1895 | 0.020 |
Why?
|
| Family | 3 | 1990 | 3144 | 0.020 |
Why?
|
| Receptors, Immunologic | 1 | 1992 | 1423 | 0.020 |
Why?
|
| Reactive Oxygen Species | 1 | 2013 | 2077 | 0.020 |
Why?
|
| Proteome | 2 | 2006 | 1790 | 0.020 |
Why?
|
| Research Design | 1 | 2022 | 5979 | 0.020 |
Why?
|
| Cross Reactions | 1 | 1988 | 841 | 0.020 |
Why?
|
| Electrophoresis, Gel, Two-Dimensional | 1 | 2006 | 279 | 0.020 |
Why?
|
| Corynebacterium | 1 | 1985 | 47 | 0.020 |
Why?
|
| Autophagy | 1 | 2013 | 1301 | 0.020 |
Why?
|
| Chromatography, High Pressure Liquid | 2 | 2007 | 1574 | 0.020 |
Why?
|
| Von Hippel-Lindau Tumor Suppressor Protein | 1 | 2007 | 290 | 0.020 |
Why?
|
| Antibody-Dependent Cell Cytotoxicity | 2 | 1985 | 304 | 0.020 |
Why?
|
| Creatine Kinase, BB Form | 1 | 2005 | 7 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2007 | 10943 | 0.020 |
Why?
|
| Microscopy, Electron, Scanning | 1 | 2007 | 962 | 0.020 |
Why?
|
| Binding Sites, Antibody | 1 | 1985 | 349 | 0.020 |
Why?
|
| Respiratory Insufficiency | 1 | 1994 | 1199 | 0.020 |
Why?
|
| Ribosomal Proteins | 1 | 2007 | 360 | 0.020 |
Why?
|
| Schizophrenic Psychology | 2 | 1990 | 1677 | 0.020 |
Why?
|
| Mice, SCID | 1 | 2010 | 2715 | 0.020 |
Why?
|
| Early Diagnosis | 1 | 2010 | 1184 | 0.020 |
Why?
|
| Amniocentesis | 1 | 1985 | 116 | 0.020 |
Why?
|
| Infant Mortality | 1 | 1990 | 754 | 0.020 |
Why?
|
| Filgrastim | 1 | 2005 | 132 | 0.020 |
Why?
|
| Muscle, Skeletal | 1 | 2000 | 4933 | 0.020 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2005 | 322 | 0.020 |
Why?
|
| Groin | 1 | 1985 | 102 | 0.020 |
Why?
|
| Asthma | 1 | 2003 | 5955 | 0.020 |
Why?
|
| Microdissection | 1 | 2004 | 152 | 0.020 |
Why?
|
| Cell Hypoxia | 1 | 2007 | 675 | 0.020 |
Why?
|
| Reproducibility of Results | 2 | 2018 | 19862 | 0.020 |
Why?
|
| Breast Neoplasms | 4 | 2007 | 20774 | 0.020 |
Why?
|
| HLA-C Antigens | 1 | 1984 | 147 | 0.020 |
Why?
|
| HEK293 Cells | 1 | 2013 | 4200 | 0.020 |
Why?
|
| Drug Costs | 1 | 2012 | 1104 | 0.020 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2010 | 1333 | 0.020 |
Why?
|
| Receptors, CXCR4 | 1 | 2009 | 726 | 0.020 |
Why?
|
| Microvilli | 1 | 1984 | 241 | 0.020 |
Why?
|
| Interleukin-4 | 1 | 1988 | 1146 | 0.010 |
Why?
|
| Interferons | 1 | 1988 | 704 | 0.010 |
Why?
|
| Liver | 3 | 1990 | 7470 | 0.010 |
Why?
|
| HLA-A Antigens | 1 | 1984 | 228 | 0.010 |
Why?
|
| Decision Trees | 1 | 2006 | 506 | 0.010 |
Why?
|
| Neutropenia | 2 | 2000 | 891 | 0.010 |
Why?
|
| Histocytochemistry | 1 | 1985 | 718 | 0.010 |
Why?
|
| Data Collection | 1 | 2013 | 3339 | 0.010 |
Why?
|
| Cyclin D1 | 1 | 2005 | 462 | 0.010 |
Why?
|
| Sequence Deletion | 2 | 2000 | 1526 | 0.010 |
Why?
|
| Staining and Labeling | 1 | 2008 | 1099 | 0.010 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2006 | 627 | 0.010 |
Why?
|
| Double-Blind Method | 4 | 2003 | 12017 | 0.010 |
Why?
|
| Gonadotropins | 2 | 1982 | 241 | 0.010 |
Why?
|
| Selenium | 1 | 2006 | 402 | 0.010 |
Why?
|
| Boston | 3 | 2005 | 9305 | 0.010 |
Why?
|
| Receptors, Transferrin | 1 | 1985 | 296 | 0.010 |
Why?
|
| Drug Evaluation | 1 | 1984 | 637 | 0.010 |
Why?
|
| Ovarian Diseases | 1 | 2004 | 139 | 0.010 |
Why?
|
| Interleukins | 1 | 1988 | 791 | 0.010 |
Why?
|
| Macrophages | 1 | 1998 | 5655 | 0.010 |
Why?
|
| In Situ Hybridization, Fluorescence | 2 | 2002 | 2638 | 0.010 |
Why?
|
| HLA-B Antigens | 1 | 1984 | 353 | 0.010 |
Why?
|
| Decision Support Techniques | 1 | 1993 | 1952 | 0.010 |
Why?
|
| Patient Protection and Affordable Care Act | 1 | 2013 | 1208 | 0.010 |
Why?
|
| Transplantation, Homologous | 2 | 1984 | 4771 | 0.010 |
Why?
|
| Chromosome Painting | 1 | 2002 | 27 | 0.010 |
Why?
|
| Stress Disorders, Post-Traumatic | 3 | 1994 | 4248 | 0.010 |
Why?
|
| Sexuality | 1 | 2004 | 174 | 0.010 |
Why?
|
| Attitude to Health | 3 | 2003 | 2051 | 0.010 |
Why?
|
| Genetic Techniques | 1 | 2005 | 435 | 0.010 |
Why?
|
| Reproduction | 2 | 2005 | 668 | 0.010 |
Why?
|
| Genomic Imprinting | 1 | 2004 | 331 | 0.010 |
Why?
|
| Biotin | 1 | 2003 | 253 | 0.010 |
Why?
|
| Oligonucleotides | 1 | 2005 | 572 | 0.010 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2009 | 1675 | 0.010 |
Why?
|
| Peritoneum | 2 | 1998 | 226 | 0.010 |
Why?
|
| Thyroid Hormones | 1 | 1984 | 390 | 0.010 |
Why?
|
| Carrier Proteins | 1 | 1995 | 5019 | 0.010 |
Why?
|
| Histological Techniques | 1 | 2002 | 198 | 0.010 |
Why?
|
| Gene Silencing | 1 | 2008 | 1538 | 0.010 |
Why?
|
| Child Abuse, Sexual | 2 | 1994 | 383 | 0.010 |
Why?
|
| Genome, Human | 2 | 2005 | 4420 | 0.010 |
Why?
|
| Mitochondria | 1 | 2015 | 3520 | 0.010 |
Why?
|
| Dimerization | 1 | 2003 | 893 | 0.010 |
Why?
|
| Polyadenylation | 1 | 2002 | 116 | 0.010 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2002 | 459 | 0.010 |
Why?
|
| Sex Factors | 1 | 1995 | 10392 | 0.010 |
Why?
|
| Age Distribution | 1 | 2007 | 2900 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2016 | 14554 | 0.010 |
Why?
|
| Hyperemesis Gravidarum | 1 | 1981 | 23 | 0.010 |
Why?
|
| Antibody Specificity | 1 | 1983 | 1094 | 0.010 |
Why?
|
| Child Abuse | 3 | 1994 | 1030 | 0.010 |
Why?
|
| Placebos | 2 | 1996 | 1677 | 0.010 |
Why?
|
| Protein Array Analysis | 1 | 2003 | 411 | 0.010 |
Why?
|
| Antigens, Surface | 1 | 1985 | 1663 | 0.010 |
Why?
|
| Endothelial Cells | 1 | 2014 | 3455 | 0.010 |
Why?
|
| Smoking | 2 | 2010 | 8969 | 0.010 |
Why?
|
| Complement C3 | 1 | 1982 | 460 | 0.010 |
Why?
|
| Pregnancy Complications | 2 | 1987 | 2861 | 0.010 |
Why?
|
| Risk Reduction Behavior | 1 | 2007 | 1123 | 0.010 |
Why?
|
| Hospitalization | 3 | 1998 | 10232 | 0.010 |
Why?
|
| Gelatin Sponge, Absorbable | 1 | 1980 | 60 | 0.010 |
Why?
|
| Psychology | 1 | 2002 | 355 | 0.010 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 1988 | 2014 | 0.010 |
Why?
|
| Inflammation Mediators | 1 | 2009 | 1889 | 0.010 |
Why?
|
| Spirituality | 1 | 2004 | 405 | 0.010 |
Why?
|
| Vaginal Diseases | 1 | 1981 | 102 | 0.010 |
Why?
|
| Contraceptive Agents, Female | 1 | 1981 | 135 | 0.010 |
Why?
|
| Computer Systems | 1 | 2001 | 483 | 0.010 |
Why?
|
| Protein Binding | 1 | 2012 | 9387 | 0.010 |
Why?
|
| Femoral Vein | 1 | 2000 | 159 | 0.010 |
Why?
|
| Psychiatric Status Rating Scales | 3 | 1994 | 6030 | 0.010 |
Why?
|
| WT1 Proteins | 1 | 2000 | 178 | 0.010 |
Why?
|
| RNA, Small Interfering | 1 | 2008 | 3504 | 0.010 |
Why?
|
| Respiratory Function Tests | 1 | 2003 | 1613 | 0.010 |
Why?
|
| Palliative Care | 1 | 1994 | 3478 | 0.010 |
Why?
|
| Tetrazolium Salts | 1 | 1998 | 96 | 0.010 |
Why?
|
| Cluster Analysis | 1 | 2006 | 2713 | 0.010 |
Why?
|
| Drug Interactions | 1 | 2003 | 1458 | 0.010 |
Why?
|
| False Negative Reactions | 1 | 1979 | 587 | 0.010 |
Why?
|
| Androgens | 1 | 2006 | 1271 | 0.010 |
Why?
|
| Vasculitis | 1 | 1982 | 521 | 0.010 |
Why?
|
| Iliac Artery | 1 | 1980 | 364 | 0.010 |
Why?
|
| Forced Expiratory Volume | 1 | 2003 | 1741 | 0.010 |
Why?
|
| Pulmonary Gas Exchange | 1 | 2000 | 381 | 0.010 |
Why?
|
| Immunity | 1 | 1984 | 1011 | 0.010 |
Why?
|
| Mesna | 1 | 1998 | 66 | 0.010 |
Why?
|
| Kinetics | 2 | 2001 | 6474 | 0.010 |
Why?
|
| Severity of Illness Index | 2 | 1994 | 15530 | 0.010 |
Why?
|
| Estrone | 1 | 1979 | 239 | 0.010 |
Why?
|
| Physicians | 1 | 2016 | 4554 | 0.010 |
Why?
|
| Systole | 1 | 2000 | 956 | 0.010 |
Why?
|
| Immunoglobulin M | 1 | 1982 | 1538 | 0.010 |
Why?
|
| Ifosfamide | 1 | 1998 | 225 | 0.010 |
Why?
|
| Liposomes | 1 | 2001 | 758 | 0.010 |
Why?
|
| DNA, Satellite | 1 | 1997 | 69 | 0.010 |
Why?
|
| Neurofibromin 1 | 1 | 1999 | 196 | 0.010 |
Why?
|
| Epitopes | 1 | 1984 | 2569 | 0.010 |
Why?
|
| Dietary Fats | 1 | 1985 | 2017 | 0.010 |
Why?
|
| Trinucleotide Repeats | 1 | 1998 | 261 | 0.010 |
Why?
|
| Counseling | 1 | 2005 | 1521 | 0.010 |
Why?
|
| Chromatography, Gel | 1 | 1977 | 668 | 0.010 |
Why?
|
| Rabbits | 1 | 1983 | 4886 | 0.010 |
Why?
|
| Vaginal Smears | 1 | 1979 | 511 | 0.010 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2000 | 902 | 0.010 |
Why?
|
| Cytodiagnosis | 1 | 1980 | 435 | 0.010 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2015 | 5171 | 0.010 |
Why?
|
| Adipose Tissue | 1 | 1988 | 3278 | 0.010 |
Why?
|
| Sex Determination Analysis | 1 | 1995 | 44 | 0.010 |
Why?
|
| Genome-Wide Association Study | 1 | 2015 | 12220 | 0.010 |
Why?
|
| Mice, Inbred C3H | 1 | 1977 | 964 | 0.010 |
Why?
|
| Laparotomy | 1 | 1998 | 474 | 0.010 |
Why?
|
| Mass Spectrometry | 1 | 2003 | 2203 | 0.010 |
Why?
|
| Tretinoin | 1 | 1999 | 516 | 0.010 |
Why?
|
| Coloring Agents | 1 | 1998 | 565 | 0.010 |
Why?
|
| Formaldehyde | 1 | 1977 | 353 | 0.010 |
Why?
|
| Hematologic Diseases | 1 | 1979 | 498 | 0.010 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2009 | 4029 | 0.010 |
Why?
|
| Statistics, Nonparametric | 1 | 2001 | 2885 | 0.010 |
Why?
|
| Drug Delivery Systems | 1 | 2007 | 2217 | 0.010 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 6 | 1 | 1995 | 122 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 2 | 1 | 1996 | 326 | 0.010 |
Why?
|
| Arteries | 1 | 1980 | 1118 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2000 | 1284 | 0.010 |
Why?
|
| Immunization, Passive | 1 | 1977 | 625 | 0.010 |
Why?
|
| Diagnostic Errors | 1 | 2002 | 1255 | 0.010 |
Why?
|
| Clone Cells | 1 | 1998 | 1692 | 0.010 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 1997 | 731 | 0.010 |
Why?
|
| Chlorambucil | 1 | 1994 | 43 | 0.010 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 11 | 1 | 1995 | 234 | 0.010 |
Why?
|
| Self Concept | 1 | 1980 | 1025 | 0.010 |
Why?
|
| Matrix Metalloproteinase 3 | 1 | 1994 | 134 | 0.010 |
Why?
|
| Mice, Inbred BALB C | 1 | 1983 | 6382 | 0.010 |
Why?
|
| Health Surveys | 1 | 2004 | 4030 | 0.010 |
Why?
|
| Protein Isoforms | 1 | 1999 | 1727 | 0.010 |
Why?
|
| Socioeconomic Factors | 1 | 2007 | 7770 | 0.010 |
Why?
|
| Mental Disorders | 1 | 1993 | 6587 | 0.010 |
Why?
|
| Neoplasm Transplantation | 1 | 1977 | 2085 | 0.010 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2012 | 15494 | 0.010 |
Why?
|
| Feeding Behavior | 1 | 1985 | 3187 | 0.010 |
Why?
|
| Postoperative Care | 1 | 1979 | 1484 | 0.010 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2000 | 1683 | 0.010 |
Why?
|
| Receptors, Interferon | 1 | 1992 | 115 | 0.010 |
Why?
|
| Hospitals, Veterans | 1 | 1994 | 404 | 0.010 |
Why?
|
| RNA | 1 | 2002 | 2747 | 0.010 |
Why?
|
| Linear Models | 1 | 2002 | 5948 | 0.010 |
Why?
|
| Neoplasms, Experimental | 1 | 1977 | 1274 | 0.010 |
Why?
|
| Chromosome Banding | 1 | 1991 | 278 | 0.010 |
Why?
|
| Genomics | 1 | 2008 | 5692 | 0.010 |
Why?
|
| Molecular Weight | 2 | 1984 | 2255 | 0.010 |
Why?
|
| DNA Primers | 1 | 1996 | 2892 | 0.010 |
Why?
|
| Pilot Projects | 1 | 2005 | 8297 | 0.010 |
Why?
|
| DNA | 1 | 2005 | 7289 | 0.010 |
Why?
|
| Salpingostomy | 1 | 1990 | 11 | 0.010 |
Why?
|
| Disease Susceptibility | 1 | 1998 | 1780 | 0.010 |
Why?
|
| Peptides | 1 | 2003 | 4392 | 0.010 |
Why?
|
| Immunoblotting | 1 | 1994 | 1683 | 0.010 |
Why?
|
| Thiazoles | 1 | 1998 | 1484 | 0.010 |
Why?
|
| Binding, Competitive | 1 | 1992 | 1159 | 0.010 |
Why?
|
| Pleural Effusion | 1 | 1994 | 338 | 0.010 |
Why?
|
| Radionuclide Imaging | 2 | 1990 | 2027 | 0.010 |
Why?
|
| Immunoglobulin G | 1 | 1982 | 4554 | 0.010 |
Why?
|
| Follicle Stimulating Hormone | 2 | 1986 | 738 | 0.010 |
Why?
|
| Antipsychotic Agents | 1 | 1984 | 3058 | 0.010 |
Why?
|
| Technetium Tc 99m Sulfur Colloid | 1 | 1990 | 66 | 0.010 |
Why?
|
| Anxiety | 1 | 2005 | 4279 | 0.010 |
Why?
|
| Interleukin-1 | 1 | 1993 | 1262 | 0.010 |
Why?
|
| Hemodynamics | 1 | 2000 | 4197 | 0.010 |
Why?
|
| Bone Marrow | 1 | 1980 | 2941 | 0.010 |
Why?
|
| Comorbidity | 2 | 1994 | 10372 | 0.010 |
Why?
|
| Aspartate Aminotransferases | 1 | 1991 | 418 | 0.010 |
Why?
|
| Pain | 1 | 2004 | 4961 | 0.010 |
Why?
|
| Granulocytes | 1 | 1991 | 546 | 0.010 |
Why?
|
| Glycerolphosphate Dehydrogenase | 1 | 1988 | 39 | 0.010 |
Why?
|
| Luteinizing Hormone | 2 | 1982 | 864 | 0.010 |
Why?
|
| Hemorrhage | 1 | 1981 | 3461 | 0.010 |
Why?
|
| Receptors, Somatomedin | 1 | 1988 | 57 | 0.010 |
Why?
|
| Meningeal Neoplasms | 1 | 1978 | 1241 | 0.010 |
Why?
|
| Oxygen | 1 | 2000 | 4169 | 0.010 |
Why?
|
| Evaluation Studies as Topic | 1 | 1991 | 1676 | 0.000 |
Why?
|
| Pituitary Hormones, Anterior | 1 | 1988 | 65 | 0.000 |
Why?
|
| Platelet Count | 1 | 1991 | 780 | 0.000 |
Why?
|
| DNA, Recombinant | 1 | 1988 | 475 | 0.000 |
Why?
|
| Prevalence | 2 | 1994 | 15194 | 0.000 |
Why?
|
| Heart | 1 | 2000 | 4462 | 0.000 |
Why?
|
| Placental Lactogen | 1 | 1986 | 17 | 0.000 |
Why?
|
| Monitoring, Physiologic | 2 | 1985 | 1737 | 0.000 |
Why?
|
| Life Expectancy | 1 | 1993 | 1183 | 0.000 |
Why?
|
| Interpersonal Relations | 2 | 1985 | 1423 | 0.000 |
Why?
|
| Dyspnea | 1 | 1994 | 1298 | 0.000 |
Why?
|
| Affect | 1 | 1994 | 1473 | 0.000 |
Why?
|
| Colonic Neoplasms | 1 | 1998 | 2542 | 0.000 |
Why?
|
| Obesity, Morbid | 1 | 1996 | 1204 | 0.000 |
Why?
|
| Health Services Needs and Demand | 1 | 1994 | 1411 | 0.000 |
Why?
|
| Education | 1 | 1989 | 543 | 0.000 |
Why?
|
| Mood Disorders | 1 | 1992 | 1106 | 0.000 |
Why?
|
| Chronic Disease | 1 | 2000 | 9144 | 0.000 |
Why?
|
| Flupenthixol | 1 | 1984 | 12 | 0.000 |
Why?
|
| Fluphenazine | 1 | 1984 | 36 | 0.000 |
Why?
|
| Paternity | 1 | 1984 | 16 | 0.000 |
Why?
|
| Reoperation | 1 | 1994 | 4200 | 0.000 |
Why?
|
| Monocytes | 1 | 1994 | 2593 | 0.000 |
Why?
|
| Receptor, Insulin | 1 | 1988 | 846 | 0.000 |
Why?
|
| Hypersensitivity, Delayed | 1 | 1985 | 485 | 0.000 |
Why?
|
| Prolactin | 1 | 1986 | 669 | 0.000 |
Why?
|
| Exercise | 1 | 2000 | 5611 | 0.000 |
Why?
|
| Ambulatory Care | 1 | 1994 | 2706 | 0.000 |
Why?
|
| Binding Sites | 1 | 1992 | 6115 | 0.000 |
Why?
|
| Analysis of Variance | 1 | 1992 | 6365 | 0.000 |
Why?
|
| Hypertension, Pulmonary | 1 | 1994 | 1527 | 0.000 |
Why?
|
| Extracorporeal Membrane Oxygenation | 1 | 1994 | 1348 | 0.000 |
Why?
|
| Complement Activating Enzymes | 1 | 1982 | 28 | 0.000 |
Why?
|
| Triiodothyronine | 1 | 1984 | 494 | 0.000 |
Why?
|
| Respiration, Artificial | 1 | 1994 | 2566 | 0.000 |
Why?
|
| Injections, Intraperitoneal | 1 | 1983 | 424 | 0.000 |
Why?
|
| Complement C1q | 1 | 1982 | 92 | 0.000 |
Why?
|
| Carcinoembryonic Antigen | 1 | 1983 | 347 | 0.000 |
Why?
|
| Ranidae | 1 | 1982 | 33 | 0.000 |
Why?
|
| Paraneoplastic Endocrine Syndromes | 1 | 1981 | 31 | 0.000 |
Why?
|
| Veterans | 1 | 1994 | 2513 | 0.000 |
Why?
|
| Thyroxine | 1 | 1984 | 666 | 0.000 |
Why?
|
| Interview, Psychological | 1 | 1984 | 812 | 0.000 |
Why?
|
| Immunoglobulins | 1 | 1984 | 880 | 0.000 |
Why?
|
| Random Allocation | 1 | 1985 | 2425 | 0.000 |
Why?
|
| Delayed-Action Preparations | 1 | 1984 | 965 | 0.000 |
Why?
|
| Cost-Benefit Analysis | 1 | 1993 | 5385 | 0.000 |
Why?
|
| Depressive Disorder | 1 | 1993 | 3748 | 0.000 |
Why?
|
| Dehydroepiandrosterone Sulfate | 1 | 1981 | 238 | 0.000 |
Why?
|
| Dehydroepiandrosterone | 1 | 1981 | 252 | 0.000 |
Why?
|
| Clomiphene | 1 | 1979 | 72 | 0.000 |
Why?
|
| Congenital Abnormalities | 1 | 1984 | 707 | 0.000 |
Why?
|
| Biological Assay | 1 | 1982 | 652 | 0.000 |
Why?
|
| Polyethylene Glycols | 1 | 1984 | 1181 | 0.000 |
Why?
|
| Immunoassay | 1 | 1982 | 752 | 0.000 |
Why?
|
| Reference Standards | 1 | 1982 | 1020 | 0.000 |
Why?
|
| Thyroid Gland | 1 | 1984 | 1172 | 0.000 |
Why?
|
| Health Education | 1 | 1984 | 1053 | 0.000 |
Why?
|
| Communication | 1 | 1990 | 3728 | 0.000 |
Why?
|
| Testis | 1 | 1979 | 800 | 0.000 |
Why?
|
| Hypothalamo-Hypophyseal System | 1 | 1979 | 703 | 0.000 |
Why?
|
| Insulin | 1 | 1988 | 6575 | 0.000 |
Why?
|
| Cerebellar Neoplasms | 1 | 1978 | 585 | 0.000 |
Why?
|
| Testosterone | 1 | 1979 | 2401 | 0.000 |
Why?
|
| Body Weight | 1 | 1979 | 4664 | 0.000 |
Why?
|
| Rats | 1 | 1982 | 24265 | 0.000 |
Why?
|